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Abstract: Ankaferd hemostat (ABS; Ankaferd Blood Stopper®, İstanbul, Turkey) is a hemostatic agent having an impact on red blood cell–
fibrinogen interactions. The hemostatic effect of ABS depends upon the quick promotion of a protein network, particularly fibrinogen
gamma, in relation to the erythrocyte aggregation. The entire physiological process involves ABS-induced formation of the protein
network by vital erythrocyte aggregation. Vital erythrocyte aggregation occurs with the spectrine, ankyrin, and actin proteins on the
membrane of the red blood cells. ABS notably affects cell metabolism and cell cycle mechanisms. Meanwhile, ABS has antiproliferative
effects on cancer cells. The aim of this review is to assess molecular basis of ABS as a hemostatic drug. The literature search on ABS
was performed in PubMed, Web of Science (SCI expanded), and Scopus with particular focus on the studies of molecular basis of ABS,
in vivo research, case series, and controlled randomized clinical studies. Current perspective for the utilization of ABS is to provide
hemostasis with accelerating wound healing. Future controlled trials are needed to elucidate the pleiotropic clinical effects of ABS such
as antineoplastic, antiinflammatory, antiinfective, antifungal, and antioxidative effects.
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1. Introduction
Ankaferd hemostat (ABS; Ankaferd Blood Stopper®,
İstanbul, Turkey) had been traditionally practiced in
Anatolia as a hemostatic agent for centuries. It is a hemostatic
agent having an impact on the red blood cell–fibrinogen
interactions [1]. ABS contains a standardized combination
of the plants named as Glycyrrhiza glabra, Thymus vulgaris,
Alpinia ofﬁcinarum, Vitis vinifera, and Urtica dioica [2,3].
ABS shows its hemostatic effect via affecting the physiology
of red blood cells [1]. ABS has an expanding spectrum
of clinical indications. There are distinct and important
molecular components of the ABS-induced hemostatic
network. Vital erythrocyte aggregation is established with
spectrin, ankyrin, and actin proteins on the membranes of
red blood cells. Recently, ABS has been introduced as a new
topical hemostatic agent when conventional methods for
the management of clinical bleeding are not effective [4–6].
ABS is also effective in patients with primary or secondary
hemostatic dysfunction as well as in patients with normal
hemostatic parameters and bleeding [7,8]. The aim of this
review is to assess essential molecular basis of ABS as a
hemostatic drug.
2. Proteomic analyses of ABS
Demiralp et al. disclosed the protein library of ABS via
MALDI-TOF analysis. The whole physiological activity

involves ABS-induced formation of the protein network by
vital erythrocyte aggregation. Vital erythrocyte aggregation
occurs with the spectrin, ankyrin, and actin proteins on
the membrane of the red blood cells. Mandatory erythroid
proteins (ankyrin recurrent and FYVE bundle containing
protein 1, spectrin alpha, actin-depolymerization factor,
actin-depolymerizing factor, LIM bundle and actin
binding subunit 1 isoform a, LIM bundle and actin binding
subunit 1 isoform b, NADP-dependent malic enzyme,
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex,
mitochondrial NADP (+)-dependent malic enzyme 3,
ribulose bisphosphate- carboxylase large chain, maturase
K) and the necessary ATP bioenergy (ATP synthase, ATP
synthase beta subunit, ATP synthase alpha subunit, ATPbinding protein C12, TP synthase H+ transporter protein,
ADF, and alpha-1, 2 glycosyltransferase ALG10-A) are
the main components of protein library of ABS [9]. ABS
also regulates GATA/FOG transcription system affecting
erythroid functions and urotensin II [9,10]. Urotensin
II, a very important component of ABS, also represents
the relationship between injured vascular endothelium,
adhesive proteins, and active erythroid cells [9].
ABS particularly affects cell metabolism and cell cycle
mechanism and has antiproliferative effects on cancer
cells. ABS affects the potential targets on cancer treatment
such as SND1, KPNA2, and PARK7. Another important
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outcome was the upregulation of tumor suppressor
proteins UCHL1 and RPL5. In particular, RPL5 directly
activates the p53 apoptotic pathway and causes apoptosis
[11]. Protein–protein interaction networks are important
interactions in understanding cellular processes such as
metabolism, signal transduction, and drug resistance.
The interactions of the identified proteins were mapped
as depicted in Figure 1. These proteins were linked and
worked together to protect the Caco-2 cells against the
effect of ABS as depicted in Figure 2 [11].
3. The effects of ABS on transcription factors
The effects of ABS on transcription factors and erythrocyte
protein profile in HUVEC endothelium were investigated.
In one study, ABS was shown to be highly effective not
only outside the cells but also inside the cell at low doses
(5 μL) and could affect many molecular mechanisms
in endothelial cells. The level of the activity of the
transcription factors (AP2, AR, CREATF1, CREB, E2F15, E2F6, EGR, GATA, HNF1, ISRE, Myc-Max, NF1, NFκB, p53, PPAR, SMAD2/3, SP1, TRE/AP1, and YY1)
were significantly increased in response to ABS. Those
transcription factors regulate a wide variety of biological
functions, including hemostasis, infection, cellular
proliferation, and inflammation [12]. GATA regulates
erythroid differentiation and promotes the production
of erythroid proteins such as spectin. In another study,
GATA activity was significantly increased after ABS
administration [12]. ABS importantly increased the level
of activity of the following transcription factors; AP2, AR,
CRE-ATF1, CREB, E2F1-5, E2F6, EGR, ISRE, Myc-Max,
NF1, NF-κB, p53, PPAR, SMAD2/3, SP1, TRE/AP1, and

YY1. Those regulator molecules affect different steps of
cellular proliferation, such as cell cycle regulation, signal
transduction, angiogenesis, apoptosis, inflammation,
acute phase reaction, immunity, and several metabolic
molecular pathways [12].
4. The effects of ABS on the cellular biology
The antineoplastic effect of ABS was preliminarily defined
in cancer cell lines [13,14]. In a study, a dose-dependent
inhibition of cell proliferation and a significant reduction
in the survival of SAOS-2 cells were observed after ABS
administration [13]. In another study, the antineoplastic
effects of ABS on colon cancer cells were also defined.
Following the addition of ABS to the culture medium,
the inhibition of cellular reproduction, and loss in the
viabilities of human colon CaCo-2 cells were observed
[14]. Mumcuoglu et al. demonstrated that, depending
on the concentration and duration of the application,
ABS could cause apoptosis via regulating PAR1 and p53independent p21 involvement in apoptosis stimulation
within leukemia cells [15]. Likewise, Akalın et al. showed
that the antiproliferative effects of ABS on lymphoid
neoplastic cells (B-CLL and RAJI tumor cell lines).
First, the inflation of the hematopoietic tumor cells was
observed with the addition of ABS solution. The inflation
and proliferation continued on B-CLL cells at day 3
and produced aggregation islands [16]. Turk et al. also
demonstrated that the most resistant cell type was SKMEL-10 and the least resistant neoplastic cell type was
A2058. The anticancer effect of ABS was also evident on
light microscopic images of untreated M307 primary
cells [17]. Another study revealed that ABS induces DNA

Figure 1. (a) The Map of down-regulated and (b) the Map of upregulated proteins with the administration of Ankaferd hemostat
(ABS) upon human colon cancer cell line, CACO-2. (reproduced with the open access policy of the Journal; Bio Med Res1)
1

https://www.hindawi.com/journals/bmri/2019/5268031/fig4/
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damage, apoptosis, and cytotoxic activity via generating
reactive oxygen species in melanoma cell lines [18]. One
study investigated the biological activity of ABS-derived
iron on iron-regulated genes during iron-deficiency
anemia. The results showed that ABS-derived ironinfluenced transcriptions of iron-regulated marker genes,
including divalent metal transporter (Dmt1), transferrin
receptor (TfR), ankyrin repeat domain 37 (Ankrd37), and
hepcidin (Hamp). ABS might have an ability to reduce
levels of iron deficiency anemia [19].
5. The principal effect of ABS on hemostatic processes
ABS contains essential erythroid proteins such as
spectrin-alpha, actin depolymerization factor, NADH
dehydrogenase (ubiquinone) 1-alpha subcomplex,
mitochondrial NADP (+)-dependent malic enzyme and the
required adenosine triphosphate (ATP) bioenergy source
[1]. In the presence of ABS, vital erythrocyte aggregation
occurs via spectin and ankyrin receptors in red blood cell
membranes [20]. Moreover, there are distinct mechanisms

affecting hemostatic plug formation. ABS also affects
different regulator molecules such as protein-2 (AP2),
androgen receptor (AR), cyclic AMP response element
or activating transcription factor-1 (CRE-ATF1), cyclic
AMP response element binding protein (CREB), E2F15, E2F6, interferon (IFN)-stimulated response element
(ISRE), Myc-Max, nuclear factor-1 (NF-1), protein-53 or
tumor protein-53 (p53), peroxisome proliferator-activated
receptor (PPAR), and Yin Yang-1 (YY1) transcription
factors. Those regulatory molecules affect cellular vascular
hemostasis, angiogenesis, signal transduction, apoptosis,
inflammation, acute-phase reaction, immunity and several
metabolic pathways [9].
Nanotechnological approaches were applied to further
develop ABS drug [21,22]. Using the classical ABS solution
to create active hemostasis during partial nephrectomy
could not be so efficient due to the insufficient contact
surface between the ABS hemostatic liquid agent and
the bleeding area. In order to expand the contact surface,
Huri et al. generated a chimeric hemostatic agent, ABS

Figure 2. (a) The classification of upregulated proteins in cellular component. (b) Classification of upregulated proteins in
organelles. (c) Classification of upregulated proteins in cellular processes affected by the administration of Ankaferd hemostat
(ABS) in the pathobiology of colon cancer cell line 1.
1

https://www.hindawi.com/journals/bmri/2019/5268031/fig3/
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nanohemostat, via combining a self-assembling peptide
amphiphile molecule with the traditional ABS as depicted
in Figure 3. ABS nanohemostat has comparable hemostatic
efficacy to the traditional ABS in the partial nephrectomy
experimental model as shown in Figure 4. Clarification of
the cellular and tissue effects of this chimeric compound
may open new avenues for novel experimental and clinical
studies in the hemostasis [22].
Coagulation proteins (Factors V, VII, VIII, IX, X, XI,
and XIII), prothrombin time (PT) and activated partial
thromboplastin time (aPTT) were normal during ABS
administration. However, it was observed that thrombin
time (TT) was prolonged due to fibrinogen gamma [1]. On
the contrary, a recent hemorheological study showed that
ABS has antierythrocyte aggregation effect. ABS inhibits
pathological aggregation of red blood cells. Antithrombotic
clinical effects of ABS could be ascribed to the paradoxal
antierythrocyte aggregation actions of the drug [23].
6. Preclinical in vivo animal models of ABS
Numerous studies have been conducted on preclinical
animal models to demonstrate the efficacy and safety
of ABS [24–29]. Kuru et al. observed that rectal
administration of ABS showed positive effects on bursting
pressures, tissue prolidase and hydroxyproline levels and
the histopathological findings of colonic anastomosis [30].
The administration of ABS to the superficial and deep
abdominal lacerations could control bleeding successfully
[24]. In another animal study, the effectiveness of ABS

was compared to several conventional antihemorrhagic
methods. Hemostasis was successfully achieved via ABS
application. Moreover, warm ischemia times decreased by
ABS [31]. In another study, the rats underwent femoral
vein puncture. One subgroup was treated with ABS
tampon or spray and the other control group was left
untreated. After two weeks, each group underwent partial
tissue excision from the same femoral region, brain, heart,
kidney, and liver. ABS was observed to stop the bleeding.
There were no histopathological changes at the tissue
level and no pathological effects in other organ tissues
under light microscope [32]. Beyazit et al. investigated
the macroscopic and microscopic changes in the cervical
mucosa and immunohistochemical staining for IL-1 β
in response to ABS treatment in a chemically induced
cervicitis model of rats. The study showed that ABS had
significant protective effects on vascular congestion and
cervical erosion [33].
7. Clinical usage of ABS
ABS has hemostatic, antithrombotic, antiinfective,
antineoplastic, and wound healing effects. ABS has also
been employed in controlled clinical trials as depicted in
Table.
7.1. The usage of Ankaferd Hemostat (ABS) in bleeding
Clinical studies have demonstrated that ABS can be safely
and effectively used in surgical and dental procedures
in patients with normal and abnormal hemostasis. Huri

Figure 3. The presentation of ABS Nanohemostat formation by self-assembly of peptide amphiphile molecules into nanofibers
upon addition of Ankaferd hemostat solution1.
1

https://www.hindawi.com/journals/ijbm/2013/949460/fig2/
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et al. reported a case indicating the efficacy of ABS in a
patient with prostate adenocarcinoma undergoing radical
retropubic prostatectomy. Hemostasis was achieved with
ABS in active bleeding tissues during radical prostatectomy
[49]. In another study, ABS was successfully applied to
control bleeding without suturing the renal parenchyma.
ABS was shown to have a significant effect on active
hemostasis during urogenital operations [50].
Gastrointestinal (GI) bleeding is an important
life-threatening condition and a common cause of
hospitalization. During the research for a further
hemostatic agent for the management of GI hemorrhages,
current evidence suggests that ABS could have an efficient
hemostatic effect for the “difficult-to-manage” subtypes
of GI hemorrhages [51–53]. Ozaslan et al. showed that
five adult patients with bleeding peptic ulcer disease,
in which ABS was used as a primary hemostatic agent,
were reported to achieve success in control of bleeding
within minutes [54]. Additionally, Purnak et al. reported
a successful hemostasis in a patient with a bleeding peptic

ulcer complicated with defective hemostasis [55]. There
are also numerous case reports showing that ABS was
used safely in GI bleeding in infants and children. The
pediatric experience with ABS in an infant with bleeding
peptic ulcer had been recently demonstrated. ABS was
applied over the ulcer surface and in a very short period
white-grey adherent clot was developed on the ulcer and
bleeding ceased [56].
Yasar et al. evaluated the efficacy of ABS tamponade in
the control of intra-operative bleeding occurring during
adenoidectomy performed in children under the age of 12
[45]. In all countries, cardiac surgeries are increasing and
parallel to this, sternotomy healing and bleeding problems
cause surgeons to search for new options and use several
new techniques and materials. Ergeneoglu et al. showed
that applying ABS was a useful different technique for the
control of sternal bleeding during cardiac surgery [57].
Another study showed that the local use of ABS decreases
bleeding significantly during the operation. Therefore,
transfusion requirements of erythrocyte suspension and

Figure 4. Erythrocyte aggregation in glomerular field and interstitium in ABS Nanohemostat group (20–40xHE)1.
1

https://www.hindawi.com/journals/ijbm/2013/949460/fig7/
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Table. Clinical studies of Ankaferd hemostat.
Clinical study

Study population

Study design and results

Koyuncu et al.

Advances in therapy 2019;
36: 1143-1149 [34]

80 patients with bleeding
associated with extremity
lacera-tions

ABS appears to be useful in controlling bleeding due to lacerations on the extremities
in adults. Bleeding was stopped significantly faster and recurred significantly less
frequently in the ABS-treated group.

Gorgulu et al.

J Interven Cardiol. 2018;
1-7 [35]

630 patients underwent
coronary angiography

It is possible that ABS can completely prevent radial artery occlusion and ABS is
effective in preventing bleeding complications.

Yaman et al.

Eur Arch Paediatr Dentist
2012; 13: 197-202 [36]

30 patients with dental
problems

ABS was compared with formocresol for pain, swelling, mobility, resorption, furcation,
and periapical bone destruction. ABS was as effective as formocresol for a pulp dressing
of primary molar.

Iynen et al.

Int J Pediatr Otorhinolaryngol
2011; 75: 1292-1295 [37]

90 patients who underwent
adenoidectomy

Clinical effect of ABS on hemostasis on peri-adenoidectomy period was evaluated. ABS
decreases the duration and quantity of blood loss postadenoidectomy and increases
postoperative quality of life.

Teker et al.

European Archives of OtoRhino-Laryngology, 2010,
267.9: 1377-1381 [38]

49 patients with epistaxis

Hemostasis by ABS was compared to hemostasis by phenylephrine. ABS was an
effective, safe, rapid, and simple alternative to the phenylephrine in patients with
epistaxis.

Teker et al.

Int J Pediatr Otorhinolaryngol
2009; 73: 1742-1745 [39]

47 patients with chronic
tonsillitis, tonsillar hypertrophy, ABS reduced intraoperative hemorrhage and operation time for patients with chronic
and obstructive sleep apnea
tonsillitis, tonsillar hypertrophy, and obstructive sleep apnea syndrome
syndrome

Guler et al.

J Invest Surg 2011; 24:
205–210 [40]

61 patients who underwent
thyroidectomy

ABS and hemostasis by conventional technique (HCT) groups were compared in terms
of operation time, postoperative drainage, duration of postoperative hospitalization and
complications. ABS was more effective than HCT to control hemorrhage following total
thyroidectomy

Pamuk et al.

J Periodontal Res 2016;
51: 540-547 [41]

15 patients with periodontitis

ABS improved soft tissue healing during the periodontal defect filling by the ACB by
stimulating angiogenesis and vascular endothelial cell function.

Istanbulluoglu et al.

45 of the patients underwent tubeless percutaneous nephrolithotomy (PCNL) with
J Endourol 2013; 27: 1126-1130 90 patients who underwent
the use of ABS as a hemostatic agent, whereas the remaining ones underwent tubeless
[42]
percutaneous nephrolithotomy
PCNL without ABS. ABS is a potent and safe hemostatic agent in tubeless PCNL.

Amer et al.

Eur J Dent 2014; 8: 475-480
[43]

205 patients who underwent
dental procedures

Patients were selected so that 80 patients have INR values of ≤2, whereas the remaining
patients have the INR values ranging from 2 to 3 and the procedures were applied.
ABS is an effective hemostatic agent comparable to tranexamic acid in controlling
postextraction bleeding in AOT patients of INR values ≤3.
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Authors

Table. (Continued).
50 patients who underwent
CABG surgery

25 CABG patients received a high-dose clopidogrel (600 mg) and 300 mg ASA have
been included in the study (ABC group). Twenty-five patients have also been included
as control group. Local use of ABC reduced bleeding from the mediastinum after
CABG.

Yasar et al.

Afr J Tradit Complem 2011;
8: 444-446 [45]

60 patients who underwent
adenoidectomy

A significantly shorter duration of bleeding and a lower number of packs are needed
to obtain ABS tamponade-induced hemostasis during adenoidectomy as compared to
saline soaked gauze sponge application.

Akpinar et al.

Heart Surg Forum 2015; 18:
E118–E123 [46]

50 patients who underwent
CABG

Twenty-five CABG patients premedicated with clopidogrel and ASA were included
and 25 patients who were premedicated with the same antiplatelet agents were as a
control group. The use of local ABS decreases bleeding and transfusion requirements in
patients premedicated with clopidogrel and ASA undergoing emergent CABG.

Eyi et al.

40 pregnant women who
Clin Exp Obstet Gynecol 2013;
required a mediolateral
40: 141-143 [47]
episiotomy

The patients were randomly assigned to two approaches on ABS and SS. Application of
4 mL of ABS compared to SS lessened bleeding.

Atay et al.

Int J Hematol Oncol 2015; 25:
166–171 [48]

The healing duration of oral mucositis was shorter with the topical ABS application.
Additionally hemorrhages from oral mucositis lesions were healed within 2 days with
ABS.

20 patients with oral mucositis

ACB: autogenous cortical bone greft, ABS: Ankaferd blood stopper; AOT: Oral anticoagulant therapy; CABG: coronary artery bypass grafting; ASA: acetylsalicylic acid; INR:
international normalized ratio; GIS: gastrointestinal system; GR: gingival recession; HCT: hemostasis by conventional technique; PCNL: percutaneous nephrolithotomy; SS: saline
solution; VEGF: vascular endothelial growth factor.
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Atalay et al.

Open Cardiovasc Med J 2015;
9: 18-25 [44]
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platelets decreased in patients who received clopidogrel
and ASA undergoing emergent operations [44].
7.2. The usage of ABS in wound healing
Functional proteomic analyses had defined antithrombin
and prohemostatic activities of ABS which are related
to fibrinogen gamma chain and prothrombin [58]. ABS
can improve the wound-healing process via providing
inhibition of extra cellular matrix-degrading enzymes
during wound repair. Moreover, ABS enhanced the
stimulated migration of 3T3 fibroblasts to an artificial
wounded area [59]. Plant extracts in ABS have been reported
to inhibit various enzymes. The extracts of T. vulgaris
were shown to inhibit collagenase and elastase inhibition
by 25% and 17%, respectively, while hyaluronidase was
shown to be inhibited 100% [60]. Additionally, another
study showed that ursolic acid extracted from U. dioica
exhibited elastase and collagenase inhibition activity of
24.5% and 16.2%, respectively [61]. Topal et al. showed
that the wound contraction in the ABS and silver
sulphadiazine groups was significantly higher than in the
control group on days 14, 21, and 28 and suggested that
ABS could be successfully used for burn wound healing
besides silver sulphadiazine [62]. ABS may be useful in
the treatment of acute burn lesions. It was observed that
the wounds healed rapidly with the topical application of
ABS onto the burn lesions [63]. In one study, the effect of
ABS on the cut surface of the pancreatic duct as well as
the pancreatic remnant was a safe procedure that prevents
the formation of pancreatic fistula without causing adverse
side effects such as pancreatitis [64]. Radiation-induced
esophageal ulcer in a patient with breast cancer was
completely healed with topical application [65]. It has been
shown that ABS has a protective effect against intestinal
damage in an experimental rat necrotizing enterocolitis
model due to its antioxidant, antiinflammatory, and
antiapoptotic characteristics [66]. In another study,
intravaginal ABS injection caused a significant decrease in
the number of inflammatory cells in the cervical mucosa
and ABS had significant protective effects on cervical
erosion [33]. In another animal study, it was observed
that ABS administration improved uterine fibrosis and
histopathological inflammation by lowering the level of
inflammatory markers such as IL-1 and IL-6 [67].
7.3. The usage of ABS in infections
Vitis vinifera, one of the components of ABS has potential
prebiotic effects on modulating the gut microbiota
composition and generating SCFAs that contribute to the
improvements of host health [68]. ABS was evaluated on
102 clinical isolates from both gram-negative and grampositive bacteria and four standard strains, including
MRSA ATCC 43300, MSSA ATCC 25923, P. aeruginosa
ATCC 27853 and E. coli ATCC 35218. The study showed
that ABS was significantly active against all of the bacteria
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investigated [69]. Another study disclosed that ABS is highly
effective against several gram-negative and gram-positive
bacteria including frequent foodborne microorganisms
[70]. Akkoc et al., using agar well diffusion test, found that
ABS has a high antifungal effect against Zygosaccharomyces
bailii, C albicans, Aspergillus flavus, and Aspergillus
parasiticus [71]. In another study, ABS reported that when
applied directly to Candida species, there were changes in
growth conditions [72]. The efficiency of ABS on H. pylori
was also demonstrated. Possible anti-H. pylori effect of
ABS will broaden the therapeutic spectrum of the drug
in GI lesions as peptic ulcer disease (PUD) and lymphoid
tissue (MALT) lymphomagenesis [73]. In vitro activity
of ABS against M. Tuberculosis isolates was evaluated.
It was concluded that ABS solution used topically was
active against tuberculosis bacilli in vitro. Therefore, ABS
might be used as a supportive agent in combination with
anti-tuberculosis drugs during debridement of multidrug
resistant M. tuberculosis osteomyelitis and lymphadenitis
[74]. In one study, the efficacy of ABS with hydatid
cysts was compared with other antiseptic agents. It
can be said that ABS is an effective antiseptic agent for
percutaneous interventions to treat hydatid cysts [75].
In a study, the efficacy of ABS in prophylaxis and oral
mucositis treatment in patients receiving chemotherapy in
childhood was evaluated. ABS was thought to be effective
in prophylaxis and treatment of oral mucositis secondary
to chemotherapy in childhood cancers [76].
7.4. Toxicity profile of ABS
Quantitative analysis of heavy metals in the ABS sample
revealed that there were no Pb, Cd, Hg, and As in ABS.
Chromatographic analysis of pesticide analysis in ABS
sample revealed that ABS does not contain pesticides.
In the analysis of mycotoxin detection using the HPLC
method in the ABS drug, ABS was revealed not to contain
mycotoxins (i.e. Aflatoxin B1, Aflatoxin B2, Aflatoxin G1,
and Aflatoxin G2; total aflatoxins are not present inside
ABS). GMO analyses of the detection of genetically altered
organisms in the ABS sample represented that no plasmid
extraction was performed and ABS did not have GMO
treatment during the preparation process. Dioxin analyses
in the ABS sample showed that ABS does not contain
toxic dioxin and dioxin-like chemical compounds. Thus,
the available toxicological results have shown the safety of
ABS [77].
7.5. Intratumoral ABS for controlling the growth of
solid tumors and hepatic metastases
In a previous study, the antineoplastic effects of ABS on
myeloma cell line, in vitro and plasmocytoma development
in Balb/c mice were investigated by intraperitoneal preterm
injection in vitro. The cytotoxicity of ABS against the MM
cell lines was determined by the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide-dye reduction assay
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[78]. It was shown that chemopreventive effects of ABS in
7,12-dimethylbenz[a]anthracene (DMBA) induced oral
epithelial dysplasia. Histological studies have shown that the
buccal pouches of animals treated with DMBA alone showed
up serious dysplasia while only moderate or no dysplasia were
noticed in DMBA+ABS group [79]. ABS has been used as
an embolizing agent in renal and splenic arteries by Medical
Interventional Radiology for medical nephrectomy and
splenectomy purposes [80,81]. Under fluoroscopic guidance,
2 mL of ABS mixed with 2 mL of nonionic contrast agent
(Iopromide) was slowly injected until a resistance to injection
secondary to embolization was observed. Slow flow and
stagnation were observed with fluoroscopy. Approximately
3.5–4 mL of the mixture was used for embolization [80,81].
In one study, ABS was used instead of alcohol for hepatic
embolization in mice. There was a statistically significant
difference in the development of necrosis in ABS-treated
rats compared to ethanol and saline group [82]. ABS has
antineoplastic effects in colon cancer [11]. In colon cancer
liver metastases and hepatocellular cancer patients, tumor
ablation treatment could be applied via interventional
radiology techniques in future clinical practice of ABS. In
the current technique: alcohol, N-butyl-2-cyanoacrylate, and
caustic substances are used as tumor embolizers. In clinical
practice in colon cancer liver metastases and hepatocellular
cancer patients, ABS could be used for the palliative,
adjuvant, neo-adjuvant, or supportive use via interventional
radiology techniques for the management of solid tumors.
This hypothesis should be tested in future studies.

8. Conclusion
ABS acts as a hemostatic agent in various clinical
hemorrhages and has many pleiotropic effects. The
hemostatic effect of ABS depends upon the quick
promotion of a protein network, especially fibrinogen
gamma, in relation to the erythrocyte aggregation.
The entire physiological process involves ABS-induced
formation of the protein network by vital erythrocyte
aggregation. Vital erythrocyte aggregation occurs with the
spectrine, ankyrin, and actin proteins on the membrane
of the red blood cells. ABS notably affects cell metabolism
and cell cycle mechanism. ABS has antiproliferative
effects on cancer cells. The expanding spectrum of
ABS includes antiinfective, antineoplastic, and woundhealing properties. Current perspective for using ABS is
to provide hemostasis and accelerating wound healing.
Future controlled trials are needed to show the pleiotropic
effects of ABS such as antineoplastic, antithrombotic,
antiinflammatory,
antiinfective,
antifungal,
and
antioxidative effects.
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